Teleflex Incorporated (TFX): Rasio rega marang prakiraan pendapatan
Steady demand for disposable resuscitation instruments ensures a predictable cash flow, which is reflected in the forward P/S dynamics of Teleflex Incorporated (TFX), where the 1.90 level captures the current state. Growth prospects are tied to innovative catheters and urological systems. High regulatory barriers and deep product integration into clinics securely protect the market positions of Teleflex Incorporated (TFX).
Rincian analitis perusahaan Teleflex Corp (TFX)
- rega saham lan target rega konsensus:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- data tingkat utang lan likuiditas finansial:
Rasio Total Utang marang Ekuitas Teleflex Incorporated|TFX - Rasio silihan jangka dawa marang modal|Utang jangka cendhak marang ekuitas Teleflex Incorporated|TFX - Gunggung kewajiban utang perusahaan|Utang marang nilai buku Teleflex Corp|TFX - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan Teleflex|Likuiditas cepet teleflex.com
- rincian asil keuangan lan kelipatan valuasi:
TFX - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep Teleflex Incorporated|TFX - Kapitalisasi marang bathi|Pangali Forward P/E Teleflex Inc|TFX - Rasio kapitalisasi marang bathi lan wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Teleflex Corp|TFX - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Teleflex|TFX - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan teleflex.com|TFX - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Teleflex Incorporated
- rincian pendapatan lan dodolan:
Analisis komprehensif perusahaan:Teleflex (TFX)
Investors are seeking fundamental benchmarks in the ability of Teleflex Incorporated (TFX) to monetize its R&D developments in minimally invasive surgery and urology. The forward price-to-sales ratio measures the market value of each unit of expected sales, allowing for an assessment of whether the current capitalization of Teleflex Incorporated (TFX) is justified by future revenue growth from the implementation of new catheters and hemostasis systems.
Perusahaan pesaing
Intuitive - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Danaher Corporation DHR|BDX - Rasio rega marang prakiraan pendapatan|STERIS Group (STE) - Multiplikator forward rega marang pendapatan|WST: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep baxter.com (BAX)|Rasio rega marang prakiraan pendapatan Masimo|Kapitalisasi marang prakiraan pendapatan STVN (Stevanato Group SpA)|Multiplikator forward rega marang pendapatan MMSI (Merit Medical Systems Inc)|Rasio rega marang pendapatan sing dikarepake NVST|Rasio rega marang prakiraan pendapatan ICU Medical, Inc. ICUI|Rasio kapitalisasi marang dodolan sing dikarepake dentsplysirona.com (XRAY)|LMAT: Multiplikator forward rega marang pendapatan|AtriCure Inc - Rasio rega marang pendapatan sing dikarepake|STAA: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Niagen (NAGE)|Rasio rega marang prakiraan pendapatan ZimVie Inc.|Rasio rega marang prakiraan pendapatan ANGO|Multiplikator Forward P/S CERS|TKNO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S MGRM (Monogram Technologies Inc)|STSS (Sharps Technology Inc) - Rega mangsa ngarep marang pendapatan|INFU - Rasio rega marang prakiraan pendapatan|UTMD: Rasio rega marang prakiraan pendapatan|KRMD: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Nyxoah SA (NYXH)|Multiplikator forward rega marang pendapatan MBOT|Kapitalisasi marang prakiraan pendapatan PDEX (Pro-Dex Inc.)|Multiplikator forward rega marang pendapatan ZTEK (Zentek Ltd.)|ELUT (elutia.com) - Rega forward marang dodolan|Multiplikator Forward P/S MLSS (Milestone Scientific Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake NEXGEL Inc. (NXGL)|RVP - Rasio rega marang prakiraan pendapatan|HBIO (harvardbioscience.com) - Kapitalisasi marang prakiraan pendapatan|FEMY: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Meihua Medical Technologies Co., Ltd.|Rasio rega marang prakiraan pendapatan Predictive Oncology Inc|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Callan JMB Corp CJMB|Rasio rega marang prakiraan pendapatan Atrion Corp (ATRI)|NURO (NeuroMetrix Corporation) - Rega forward marang dodolan
